Developer docs
API playgroundTry for free, no card

Search company profiles

Hera BioLabs

Full company profile

uuid0003zv7

Namestring
Hera BioLabs
Legal namestring
Hera BioLabs
Websiteurl
herabiolabs.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Hera BioLabs was a preclinical contract research organization headquartered in Lexington, Kentucky, that developed proprietary gene editing technologies and an immunodeficient animal model for drug discovery and bioprocessing applications. Founded in 2015 from gene editing technology originating at Transposagen Biopharmaceuticals, the company built its portfolio around three differentiated technology platforms: the SRG Rat—a Sprague-Dawley strain with double knockout of the Rag2 and Il2rg genes producing loss of mature B, T, and NK cells, enabling high tumor take rates (>90%) for xenograft cell lines that are prohibitively inefficient in mice; the Super piggyBac hyperactive transposase system for stable genomic integration in research and cell therapy-relevant cell types including iPSCs and T cells; and the Cas-CLOVER precision gene editing system, which uses paired gRNAs and a dimeric Clo051 nuclease architecture to deliver cleaner knockouts and larger knock-ins (20+ kb vs. CRISPR/Cas9's 7-10 kb limit) with reduced off-target effects (<1% vs. up to 10%). Hera also launched the CleanCut GS CHO platform in 2024 for therapeutic protein cell line development, expanding into the biologics manufacturing value chain.

The company's revenue model combined technology licensing (Super piggyBac, Cas-CLOVER, Harbor-IN), sale of evaluation kits and reagents at $2,500-$5,000 per kit, annual research access subscriptions of $30,000 for CleanCut CHO cells, and exclusive global distribution of the SRG Rat through Charles River Laboratories. Hera served four primary customer segments—pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, and biologics/cell therapy developers—addressing the translatability gap between preclinical mouse models and clinical outcomes.

In June 2025, Hera was acquired by Demeetra AgBio, its sister company under common ownership, consolidating commercial access to the Super piggyBac platform and CleanCut CHO cell line development under a single organization. As part of post-acquisition integration, Hera's in vitro services were absorbed into Demeetra's R&D operations while the in vivo services group was wound down, with Demeetra now positioned as the definitive commercial licensing source for the consolidated gene editing IP portfolio.

Short descriptiontext

Hera BioLabs was a Lexington, Kentucky preclinical CRO that developed gene editing technologies (Super piggyBac, Cas-CLOVER, CleanCut CHO) and the SRG Rat immunodeficient model for pharma, biotech, and academic researchers. Acquired by Demeetra AgBio in June 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical contract research, gene editing technologies, immunodeficient animal models, cell line development, xenograft research models
Industry3 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Preclinical Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary gene editing technologies (Super piggyBac, Cas-CLOVER) to pharmaceutical and biotech companies for research, development, and commercial applications in drug discovery and cell line development.

herabiolabs.com
2SRG Rat Model Distribution
TypeOne Time License
Description

Sale and distribution of the SRG Rat immunodeficient model through exclusive partnership with Charles River Laboratories. Hera retains technology rights while CRL handles breeding and global distribution.

herabiolabs.com
3Gene Editing Reagents and Evaluation Kits
TypeOne Time License
Description

Sale of research evaluation kits and reagents including Cas-CLOVER mRNA, Super piggyBac mRNA, transposons, and Harbor-IN products for internal benchmarking and licensing evaluation prior to commercial licensing agreements.

herabiolabs.com
4In Vitro Services (now integrated into Demeetra)
TypeProfessional Services
Description

Contract research services using proprietary technologies for cell line development and in vitro studies. These capabilities were incorporated into Demeetra's R&D operations following the acquisition, accelerating CleanCut CHO Platform development.

businesswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details4 tiers
1Cas-CLOVER Evaluation Kit for internal benchmarking
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Cas-CLOVER Evaluation Kit (3 vials, 25 µg each): $5,000. Individual Cas-CLOVER mRNA vials (25 µg): $2,500. Volume discounts available: 2-pack (10% off), 5-pack (15% off), 10-pack (20% off), 20-pack (25% off), 100-pack (50% off).

demeetra.com
2Super piggyBac Evaluation and Reagents
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Super piggyBac Evaluation Kit (SK02): $3,000. Super piggyBac mRNA (25 µg): $2,500. Transposons (10 µg): $1,000 each. Volume discounts available for multi-pack purchases.

demeetra.com
3CleanCut GS CHO Research Access
ModelSubscriptionBilling cadenceAnnual
Notes

CleanCut GS CHO cells (2 cryo-vials): $30,000/year. Includes 1-year research term with options for termination and extension.

demeetra.com
4Harbor-IN Transposase Starter Kit and Reagents
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Harbor-IN Starter Kit (SK01): $5,000. Harbor-IN mRNA (25 µg): $5,000. Volume discounts available for multi-pack purchases. Includes research and commercial materials license per purchase agreement.

demeetra.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SRG Rat
Description

Proprietary highly immunodeficient rat strain (Sprague Dawley-Rag2em2heraIl2rgem1hera/HblCrl) for xenograft and PDX studies. A SCID model with knockout mutations in Rag2 and Il2rgamma genes resulting in loss of mature B, T, and NK cells.

herabiolabs.com
Core offering1 text field

Hera BioLabs is a preclinical contract research organization that develops and licenses proprietary gene editing technologies (Super piggyBac transposase, Cas-CLOVER) and distributes a proprietary severely immunodeficient rat model (SRG Rat) for xenograft, PDX, and oncology research. Following its June 2025 acquisition by Demeetra AgBio, the company's in vitro services and CleanCut CHO cell line development platform were integrated into Demeetra's R&D operations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • High tumor take rates (>90%) for prostate cancer xenograft cell lines (VCaP, LNCaP) in SRG rats that are prohibitively inefficient in mouse models
+3 more records
Product overview1 text field

Hera BioLabs was a preclinical contract research organization specializing in gene editing technologies and immunodeficient animal models. Following its acquisition by Demeetra AgBio in June 2025, its technology portfolio was consolidated under Demeetra. The company's offerings included the SRG Rat platform (a severely immunodeficient Sprague-Dawley rat for xenograft and PDX studies), Super piggyBac transposase technology for stable genomic integration, and Cas-CLOVER precision gene editing. Hera also offered in vitro cell line development services leveraging the CleanCut CHO platform. The integrated portfolio supports drug discovery research, cell therapy development, and bioprocessing applications.

Product and service6 records
1SRG Rat (Sprague Dawley-Rag2em2heraIl2rgem1hera/HblCrl)
CategoryAnimal Model / Research Tool
Description

A highly immunodeficient rat strain created through double knockout mutations in the Rag2 and Il2rgamma genes, resulting in loss of mature B, T, and NK cells. Ideal for xenograft studies, PDX models, and engraftment of human tissue with high tumor take rates. Distributed globally through Charles River Laboratories.

2Super piggyBac Transposase
CategoryGene Editing Technology
Description

A protein-engineered piggyBac transposase variant designed for enhanced activity and high copy-number insertions in research and cell therapy relevant cell types, including iPSCs and T cells. Now licensed exclusively by Demeetra AgBio for research, development, and substantially all commercial use.

3Cas-CLOVER
CategoryGene Editing Technology
Description

A precision gene-editing system using two paired gRNAs and a dimeric architecture (Clo051 nuclease) to improve precision and reduce off-target activity relative to CRISPR/Cas9. Provides cleaner knockouts (8-50+ bp deletions) and more efficient knock-ins (20+ kb capacity) with favorable freedom-to-operate positioning for commercial cell line development.

4CleanCut GS CHO Platform
CategoryCell Line Development Platform
Description

Engineered CHO-K1 host systems including CleanCut GS CHO and CleanCut GS ADCC+ for stable, high-titer cell line development. Designed for robust expression, genetic stability, and manufacturability from day one, with seamless transition to GMP manufacturing.

5Harbor-IN Transposase
CategoryTransposase Technology
Description

A license-free, highly active mRNA transposase system specifically designed for stable cell line development in CHO and HEK293 cells, enabling insertion into transcriptionally active genomic regions.

6In Vitro Services (Cell Line Development)
CategoryContract Research Service
Description

Preclinical contract research services for cell line development. These services were incorporated into Demeetra's R&D operations following the 2025 acquisition to accelerate development of the CleanCut CHO Platform.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Eisai Co., Ltd.
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-01
Description

Eisai renewed its research license agreement for piggyBac transposase technology, allowing continued use of the genetic engineering platform for internal research activities. The renewal reflects the ongoing collaborative relationship between Demeetra (now holding rights through Hera acquisition) and Eisai. Specific terms of the agreement were not disclosed. piggyBac technology was acquired by Demeetra from Hera BioLabs in 2025.

prweb.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Demeetra AgBio completed acquisition of Hera BioLabs on June 1, 2025, securing expanded rights to the hyperactive Super piggyBac transposase platform. The transaction consolidated commercial access under one organization, removing prior uncertainty around licensing pathways and freedom-to-operate issues. Hera's in vitro services were incorporated into Demeetra's R&D to accelerate CleanCut CHO Platform development, while Hera's in vivo services group was wound down. Hera and Demeetra were sister companies under common ownership prior to the merger.

3NorthX Biologics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Strategic collaboration combining Demeetra's CleanCut GS CHO cell line with NorthX Biologics' GMP manufacturing capabilities. NorthX provides process development, analytics, biomanufacturing, and aseptic fill-finish services from facilities in Sweden, supporting clinical and commercial-stage biologics manufacturing. This partnership enables Demeetra to offer integrated cell line development to GMP manufacturing services, eliminating rebuilds and vendor handoff delays.

demeetra.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-04-15
Description

Exclusive global distribution partnership for SRG rat model. Charles River Laboratories (CRL) serves as the exclusive global distributor for SRG rats, handling all breeding, order processing, and fulfillment. CRL also offers preclinical services using the SRG platform, including oncology studies. As of April 15, 2022, all orders are placed with and fulfilled by Charles River. The partnership enables global access to the SRG rat model through CRL's established distribution network.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Taiho Pharmaceutical renewed its research license for piggyBac transposase technology. The license allows Taiho to continue leveraging the technology for internal research activities. This renewal demonstrates ongoing adoption of piggyBac technology by pharmaceutical companies for genetic engineering applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provider of genetically engineered rodent models including immunodeficient strains for oncology and immunology research; directly comparable to SRG Rat's positioning in the preclinical animal model market.

TypeBroad incumbent
Description

Large gene editing tools and engineered cell line provider (CRISPR, rAAV, cell line engineering) that competes with Cas-CLOVER and CleanCut CHO for commercial cell line development and bioprocessing workflows.

TypeDirect peer
Description

World's largest preclinical CRO and Hera's exclusive global distribution partner for the SRG Rat; operates adjacent and competing preclinical services and humanized mouse model franchises, making it both a channel and a partial substitute for Hera's offerings.

TypeEmerging player
Description

Gene editing tools and cell line engineering services company focused on CRISPR-based platforms; overlaps with Cas-CLOVER for cell line engineering customers seeking alternatives to incumbent CRISPR IP.

TypeDirect peer
Description

Provider of the NSG family of immunodeficient mice — the most established alternatives to Hera's SRG Rat for xenograft and PDX research — with decades of academic validation that Hera's rat model must displace.

TypeBroad incumbent
Description

Global CRO/CDMO with preclinical, cell line development, and biomanufacturing services; competes with Demeetra/Hera's integrated cell-line-to-GMP value proposition at much greater scale.

TypeEmerging player
Description

Provider of gene synthesis, protein engineering, and CHO cell line development tools and services; adjacent competitor in the synthetic biology and bioprocessing cell line engineering category.

TypeDirect peer
Description

Preclinical CRO specializing in oncology PDX models and in vivo services; overlaps with the SRG Rat use cases (xenograft, efficacy, translational oncology) and competes for similar pharma and biotech sponsors.

TypeDirect peer
Description

Specialist in mammalian (CHO-based) cell line development for therapeutic protein production; directly comparable to Hera's CleanCut GS CHO Platform in the bioprocessing cell line engineering space.

TypeEmerging player
Description

Transfection and gene delivery reagents company serving cell biology, bioprocessing, and gene therapy research; an adjacent competitor to Super piggyBac transposase for stable cell line engineering applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hera BioLabs

Preclinical Research Servicesherabiolabs.com

Hera BioLabs was a Lexington, Kentucky preclinical CRO that developed gene editing technologies (Super piggyBac, Cas-CLOVER, CleanCut CHO) and the SRG Rat immunodeficient model for pharma, biotech, and academic researchers. Acquired by Demeetra AgBio in June 2025.

What Hera BioLabs does

Hera BioLabs was a preclinical contract research organization headquartered in Lexington, Kentucky, that developed proprietary gene editing technologies and an immunodeficient animal model for drug discovery and bioprocessing applications. Founded in 2015 from gene editing technology originating at Transposagen Biopharmaceuticals, the company built its portfolio around three differentiated technology platforms: the SRG Rat—a Sprague-Dawley strain with double knockout of the Rag2 and Il2rg genes producing loss of mature B, T, and NK cells, enabling high tumor take rates (>90%) for xenograft cell lines that are prohibitively inefficient in mice; the Super piggyBac hyperactive transposase system for stable genomic integration in research and cell therapy-relevant cell types including iPSCs and T cells; and the Cas-CLOVER precision gene editing system, which uses paired gRNAs and a dimeric Clo051 nuclease architecture to deliver cleaner knockouts and larger knock-ins (20+ kb vs. CRISPR/Cas9's 7-10 kb limit) with reduced off-target effects (<1% vs. up to 10%). Hera also launched the CleanCut GS CHO platform in 2024 for therapeutic protein cell line development, expanding into the biologics manufacturing value chain.

The company's revenue model combined technology licensing (Super piggyBac, Cas-CLOVER, Harbor-IN), sale of evaluation kits and reagents at $2,500-$5,000 per kit, annual research access subscriptions of $30,000 for CleanCut CHO cells, and exclusive global distribution of the SRG Rat through Charles River Laboratories. Hera served four primary customer segments—pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, and biologics/cell therapy developers—addressing the translatability gap between preclinical mouse models and clinical outcomes.

In June 2025, Hera was acquired by Demeetra AgBio, its sister company under common ownership, consolidating commercial access to the Super piggyBac platform and CleanCut CHO cell line development under a single organization. As part of post-acquisition integration, Hera's in vitro services were absorbed into Demeetra's R&D operations while the in vivo services group was wound down, with Demeetra now positioned as the definitive commercial licensing source for the consolidated gene editing IP portfolio.

Hera BioLabs firmographics

Firmographics
Name
Hera BioLabs
Legal name
Hera BioLabs
Website
https://herabiolabs.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
1–10 employees
Short description
Hera BioLabs was a Lexington, Kentucky preclinical CRO that developed gene editing technologies (Super piggyBac, Cas-CLOVER, CleanCut CHO) and the SRG Rat immunodeficient model for pharma, biotech, and academic researchers. Acquired by Demeetra AgBio in June 2025.
Ownership category
akta.pro rank

Hera BioLabs industry classification

Industry
Product category
Preclinical Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Preclinical contract research
  • Gene editing technologies
  • Immunodeficient animal models
  • Cell line development
  • Xenograft research models

Where Hera BioLabs is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Hera BioLabs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: Licensing of proprietary gene editing technologies (Super piggyBac, Cas-CLOVER) to pharmaceutical and biotech companies for research, development, and commercial applications in drug discovery and cell line development.
  2. SRG Rat Model Distribution: Sale and distribution of the SRG Rat immunodeficient model through exclusive partnership with Charles River Laboratories. Hera retains technology rights while CRL handles breeding and global distribution.
  3. Gene Editing Reagents and Evaluation Kits: Sale of research evaluation kits and reagents including Cas-CLOVER mRNA, Super piggyBac mRNA, transposons, and Harbor-IN products for internal benchmarking and licensing evaluation prior to commercial licensing agreements.
  4. In Vitro Services (now integrated into Demeetra): Contract research services using proprietary technologies for cell line development and in vitro studies. These capabilities were incorporated into Demeetra's R&D operations following the acquisition, accelerating CleanCut CHO Platform development.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCas-CLOVER Evaluation Kit for internal benchmarking
One time/ perpetual licensePay-as-you-goSuper piggyBac Evaluation and Reagents
SubscriptionAnnualCleanCut GS CHO Research Access
One time/ perpetual licensePay-as-you-goHarbor-IN Transposase Starter Kit and Reagents

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Hera BioLabs product offering

Product offering

Core offering

Hera BioLabs is a preclinical contract research organization that develops and licenses proprietary gene editing technologies (Super piggyBac transposase, Cas-CLOVER) and distributes a proprietary severely immunodeficient rat model (SRG Rat) for xenograft, PDX, and oncology research. Following its June 2025 acquisition by Demeetra AgBio, the company's in vitro services and CleanCut CHO cell line development platform were integrated into Demeetra's R&D operations.

Product overview

Hera BioLabs was a preclinical contract research organization specializing in gene editing technologies and immunodeficient animal models. Following its acquisition by Demeetra AgBio in June 2025, its technology portfolio was consolidated under Demeetra. The company's offerings included the SRG Rat platform (a severely immunodeficient Sprague-Dawley rat for xenograft and PDX studies), Super piggyBac transposase technology for stable genomic integration, and Cas-CLOVER precision gene editing. Hera also offered in vitro cell line development services leveraging the CleanCut CHO platform. The integrated portfolio supports drug discovery research, cell therapy development, and bioprocessing applications.

Differentiator

Problem solved

Functional benefit

Brands

  • SRG Rat: Proprietary highly immunodeficient rat strain (Sprague Dawley-Rag2em2heraIl2rgem1hera/HblCrl) for xenograft and PDX studies. A SCID model with knockout mutations in Rag2 and Il2rgamma genes resulting in loss of mature B, T, and NK cells.

Products and services

  • SRG Rat (Sprague Dawley-Rag2em2heraIl2rgem1hera/HblCrl) A highly immunodeficient rat strain created through double knockout mutations in the Rag2 and Il2rgamma genes, resulting in loss of mature B, T, and NK cells. Ideal for xenograft studies, PDX models, and engraftment of human tissue with high tumor take rates. Distributed globally through Charles River Laboratories.
  • Super piggyBac Transposase A protein-engineered piggyBac transposase variant designed for enhanced activity and high copy-number insertions in research and cell therapy relevant cell types, including iPSCs and T cells. Now licensed exclusively by Demeetra AgBio for research, development, and substantially all commercial use.
  • Cas-CLOVER A precision gene-editing system using two paired gRNAs and a dimeric architecture (Clo051 nuclease) to improve precision and reduce off-target activity relative to CRISPR/Cas9. Provides cleaner knockouts (8-50+ bp deletions) and more efficient knock-ins (20+ kb capacity) with favorable freedom-to-operate positioning for commercial cell line development.
  • CleanCut GS CHO Platform Engineered CHO-K1 host systems including CleanCut GS CHO and CleanCut GS ADCC+ for stable, high-titer cell line development. Designed for robust expression, genetic stability, and manufacturability from day one, with seamless transition to GMP manufacturing.
  • Harbor-IN Transposase A license-free, highly active mRNA transposase system specifically designed for stable cell line development in CHO and HEK293 cells, enabling insertion into transcriptionally active genomic regions.
  • In Vitro Services (Cell Line Development) Preclinical contract research services for cell line development. These services were incorporated into Demeetra's R&D operations following the 2025 acquisition to accelerate development of the CleanCut CHO Platform.

Quantifiable outcome

  • High tumor take rates (>90%) for prostate cancer xenograft cell lines (VCaP, LNCaP) in SRG rats that are prohibitively inefficient in mouse models
  • +3 more outcomes

Companies that use Hera BioLabs

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Hera BioLabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Hera BioLabs partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor, flagship and core.

  • Eisai Co., Ltd.minorOEM/ Whitelabel/ Licensing Partner · 1 March 2026Eisai renewed its research license agreement for piggyBac transposase technology, allowing continued use of the genetic engineering platform for internal research activities. The renewal reflects the ongoing collaborative relationship between Demeetra (now holding rights through Hera acquisition) and Eisai. Specific terms of the agreement were not disclosed. piggyBac technology was acquired by Demeetra from Hera BioLabs in 2025.
  • Demeetra AgBioflagshipStrategic or Co-development Partner · 1 June 2025Demeetra AgBio completed acquisition of Hera BioLabs on June 1, 2025, securing expanded rights to the hyperactive Super piggyBac transposase platform. The transaction consolidated commercial access under one organization, removing prior uncertainty around licensing pathways and freedom-to-operate issues. Hera's in vitro services were incorporated into Demeetra's R&D to accelerate CleanCut CHO Platform development, while Hera's in vivo services group was wound down. Hera and Demeetra were sister companies under common ownership prior to the merger.
  • NorthX BiologicscoreStrategic or Co-development Partner · 1 January 2025Strategic collaboration combining Demeetra's CleanCut GS CHO cell line with NorthX Biologics' GMP manufacturing capabilities. NorthX provides process development, analytics, biomanufacturing, and aseptic fill-finish services from facilities in Sweden, supporting clinical and commercial-stage biologics manufacturing. This partnership enables Demeetra to offer integrated cell line development to GMP manufacturing services, eliminating rebuilds and vendor handoff delays.
  • Charles River LaboratoriescoreChannel Partner/ Reseller/ Distributor · 15 April 2022Exclusive global distribution partnership for SRG rat model. Charles River Laboratories (CRL) serves as the exclusive global distributor for SRG rats, handling all breeding, order processing, and fulfillment. CRL also offers preclinical services using the SRG platform, including oncology studies. As of April 15, 2022, all orders are placed with and fulfilled by Charles River. The partnership enables global access to the SRG rat model through CRL's established distribution network.
  • Taiho PharmaceuticalminorOEM/ Whitelabel/ Licensing PartnerTaiho Pharmaceutical renewed its research license for piggyBac transposase technology. The license allows Taiho to continue leveraging the technology for internal research activities. This renewal demonstrates ongoing adoption of piggyBac technology by pharmaceutical companies for genetic engineering applications.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Hera BioLabs competitors and assessment

Company assessment

Direct peers

  • Taconic Biosciences: Provider of genetically engineered rodent models including immunodeficient strains for oncology and immunology research; directly comparable to SRG Rat's positioning in the preclinical animal model market.
  • Charles River Laboratories: World's largest preclinical CRO and Hera's exclusive global distribution partner for the SRG Rat; operates adjacent and competing preclinical services and humanized mouse model franchises, making it both a channel and a partial substitute for Hera's offerings.
  • The Jackson Laboratory: Provider of the NSG family of immunodeficient mice — the most established alternatives to Hera's SRG Rat for xenograft and PDX research — with decades of academic validation that Hera's rat model must displace.
  • Crown Bioscience: Preclinical CRO specializing in oncology PDX models and in vivo services; overlaps with the SRG Rat use cases (xenograft, efficacy, translational oncology) and competes for similar pharma and biotech sponsors.
  • Selexis (a Sanofi company): Specialist in mammalian (CHO-based) cell line development for therapeutic protein production; directly comparable to Hera's CleanCut GS CHO Platform in the bioprocessing cell line engineering space.

Broad incumbents

  • Horizon Discovery (now Revvity): Large gene editing tools and engineered cell line provider (CRISPR, rAAV, cell line engineering) that competes with Cas-CLOVER and CleanCut CHO for commercial cell line development and bioprocessing workflows.
  • WuXi AppTec: Global CRO/CDMO with preclinical, cell line development, and biomanufacturing services; competes with Demeetra/Hera's integrated cell-line-to-GMP value proposition at much greater scale.

Emerging players

  • Synthego: Gene editing tools and cell line engineering services company focused on CRISPR-based platforms; overlaps with Cas-CLOVER for cell line engineering customers seeking alternatives to incumbent CRISPR IP.
  • ATUM: Provider of gene synthesis, protein engineering, and CHO cell line development tools and services; adjacent competitor in the synthetic biology and bioprocessing cell line engineering category.
  • Mirus Bio (a Gamma Biosciences company): Transfection and gene delivery reagents company serving cell biology, bioprocessing, and gene therapy research; an adjacent competitor to Super piggyBac transposase for stable cell line engineering applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Hera BioLabs social profiles

Digital presence

Hera BioLabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hera BioLabs leadership team

Management profile

Number of profiles

Profiles8 records

Hera BioLabs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hera BioLabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hera BioLabs

What does Hera BioLabs do?

Hera BioLabs is a preclinical contract research organization that develops and licenses proprietary gene editing technologies (Super piggyBac transposase, Cas-CLOVER) and distributes a proprietary severely immunodeficient rat model (SRG Rat) for xenograft, PDX, and oncology research. Following its June 2025 acquisition by Demeetra AgBio, the company's in vitro services and CleanCut CHO cell line development platform were integrated into Demeetra's R&D operations.

Is Hera BioLabs a public or private company?

Hera BioLabs is a private company. It is classified as corporate owned and is currently acquired.

When was Hera BioLabs founded?

Hera BioLabs was founded in 2015. It employs 1 to 10 people.

Where is Hera BioLabs based?

Hera BioLabs is headquartered in Lexington, United States, in the North America region.

How does Hera BioLabs make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are SRG Rat Model Distribution, gene Editing Reagents and Evaluation Kits and in Vitro Services (now integrated into Demeetra).

Who are Hera BioLabs's main competitors?

Direct peers on record are Taconic Biosciences, Charles River Laboratories, The Jackson Laboratory, Crown Bioscience and Selexis (a Sanofi company). Broad incumbents are Horizon Discovery (now Revvity) and WuXi AppTec. Emerging players are Synthego, ATUM and Mirus Bio (a Gamma Biosciences company).

Does Hera BioLabs have an API?

No public API is recorded for Hera BioLabs.

What industry is Hera BioLabs in?

Hera BioLabs's product category is Preclinical Research Services. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAJAE, Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogDemeetra Completes Acquisition of Hera BioLabs, Securing Expanded Rights to Hyperactive Super piggyBac® TransposaseDemeetra AgBio completed its acquisition of Hera BioLabs on June 1, gaining expanded rights to the hyperactive Super piggyBac transposase platform and consolidating commercial access under one organization. The transaction positions Demeetra as the definitive commercial source for licensing this technology across drug discovery, research tools, and commercial applications. As part of the integration, Demeetra incorporated Hera's in vitro services into its R&D operations to accelerate development of its CleanCut CHO Platform, while winding down the in vivo services group to focus on scalable platform development.DemeetraDemeetra Integrates Hera BioLabs, Consolidating Commercial Access to Super piggyBac®Demeetra AgBio has completed the full integration of Hera BioLabs, with the acquisition closing on June 1, 2025, expanding Demeetra's rights to the hyperactive Super piggyBac transposase platform and consolidating all licensing, development, and commercial activity under a single organization. The integration positions Demeetra as the definitive commercial source for Super piggyBac licensing across research and commercial applications, providing customers with clearer licensing pathways, downstream rights, and freedom to operate. Hera BioLabs' in vitro services capabilities have been incorporated into Demeetra's R&D operations to accelerate development of next-generation CleanCut CHO Platform engineered host cells, while in vivo services have been discontinued.YahooDemeetra Completes Acquisition of Hera BioLabs, Securing Expanded Rights to Hyperactive Super piggyBac® TransposaseDemeetra AgBio announced the completion and full integration of its acquisition of Hera BioLabs, effective June 1, securing expanded rights to the hyperactive Super piggyBac® transposase platform and establishing Demeetra as the definitive commercial source for licensing across broad fields of use. The consolidation removes historical licensing uncertainty, downstream rights issues, and freedom-to-operate barriers that had slowed adoption of transposase-based systems in regulated and commercial environments. Hera BioLabs' in vitro services have been incorporated into Demeetra's R&D operations to accelerate development of the next-generation CleanCut CHO Platform, while its in vivo services group has been wound down.MorningstarDemeetra Completes Acquisition of Hera BioLabs, Securing Expanded Rights to Hyperactive Super piggyBac® TransposaseDemeetra AgBio announced the completion and full integration of its acquisition of Hera BioLabs on June 1, securing expanded rights to the hyperactive Super piggyBac® transposase platform and establishing Demeetra as the definitive commercial source for licensing across broad fields of use. The consolidation removes prior uncertainty around licensing pathways and freedom-to-operate issues for transposase-based systems in regulated and commercial environments. As part of the integration, Hera BioLabs' in vitro services capabilities are being incorporated into Demeetra's internal R&D to accelerate development of next-generation CleanCut CHO Platform engineered host cells, while Hera BioLabs' in vivo services group has been wound down.NewswireHera BioLabs Announces Exclusive Global License With Charles RiverHera BioLabs and Charles River Laboratories announced a global license agreement to commercialize Hera's SRG rat, a highly immunocompromised model for xenograft studies. Charles River will breed, distribute, and market the rat, while Hera will provide services using the model. The collaboration aims to expand availability for preclinical research.GlobeNewswireHera BioLabs Announces Exclusive Global License With Charles RiverHera BioLabs and Charles River Laboratories announced a global license agreement to commercialize the SRG rat, a highly immunocompromised model for xenograft studies. Charles River will breed, distribute, and market the model, while Hera will provide services using it. The collaboration aims to expand the SRG rat franchise and bring the model to researchers worldwide.PrwebHera BioLabs ("Hera") and Demeetra Ag Bio ("Demeetra") announce joint launch of Cas-CLOVER™ the "clean alternative to CRISPR/Cas9 for drug discovery and bioprocessing"Hera BioLabs and Demeetra AgBio announced the joint launch of Cas-CLOVER, a dimeric gene-editing system that claims no off-target mutations. The system uses two guide RNAs and a proprietary Clo51 nuclease, and has been validated in CHO cell lines for bioprocessing. Licensing and evaluation opportunities are available for research and commercial use.